Cara Therapeutics (CARA) Physician Survey on IV Korsuva Offers Encouraging Feedback - Piper Sandler
Tweet Send to a Friend
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $30.00 price target on Cara Therapeutics (NASDAQ: CARA) after conducting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE